Blood Cancer Talks

Episode 36. ASH 2023 Lymphoma Recap with Dr. Toby Eyre

Dec 20, 2023

Dr. Toby Eyre, a consultant haematologist at the University of Oxford in the UK, joins the hosts to review the hottest updates in lymphoma from the ASH 2023 meeting. They discuss topics like the promising results of a novel triplet treatment for mantle cell lymphoma and the challenges of conducting trials in high-risk groups. They also explore the question of stopping therapy without consolidation, the use of a BCL2 inhibitor in lymphoma treatment, and the comparison of different treatments for CLL and Hodgkin lymphoma.

50:59

Creator website

Episode guests

Toby Eyre

AI Summary

AI Chapters

Episode notes

Podcast summary created with Snipd AI

Quick takeaways

The BOVen trial demonstrated promising results for TP53-mutated mantle cell lymphoma, with a high complete response rate and improved progression-free survival.

The SYMPATICO trial suggests a potential new standard of care for relapsed and refractory mantle cell lymphoma using Ibrutinib plus phonetic lacs with the addition of rituximab.

The FLAIR trial showed the advantage of MRD-guided therapy with Ibrutinib plus venetoclax in previously untreated CLL patients, leading to improved progression-free survival and overall survival.

Deep dives

The Bovin trial shows promising results for TP53-mutated mantle cell lymphoma

The Bovin trial focused on TP53-mutated mantle cell lymphoma, a high-risk subgroup with poor outcomes. The trial combined Zana-brute plus phonetic lacs and a bit of twos map. The results showed a high complete response rate and undetectable minimal residual disease rates. Two-year progression-free survival was over 70%, representing a significant advancement in treatment options for this high-risk patient population.

Introduction

4min

Challenges and Future Approaches in Studying TP53 Mutations

2min

Exploring the Question of Stopping Therapy without Consolidation in Hypothetical Scenario

2min

Triplet Regimen and BCL2 Inhibitor in Lymphoma Treatment

9min

Comparing FCR and M.R.D.-guided therapy in CLL patients

16min

Comparison of NIVOLAMAB AVD and Brantaximabidotin AVD in Elderly/Unfit Patients with Hodgkin Lymphoma

18min

In this episode, we review the hottest updates in lymphoma from the American Society of Hematology 2023 meeting with Dr Toby Eyre, a consultant haematologist at the University of Oxford in the UK.

Here are the abstracts that were discussed:

Mantle Cell Lymphoma

1. BOVen trial-A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Treatment-Naïve, TP53-Mutant Mantle Cell Lymphoma

https://ash.confex.com/ash/2023/webprogram/Paper180069.html

2. SYMPATICO Trial: Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma (Late Breaking Abstract)

https://ash.confex.com/ash/2023/webprogram/Paper191921.html

Chronic Lymphocytic Leukemia

1. FLAIR trial: Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

Link for simultaneous NEJM publication: https://www.nejm.org/doi/10.1056/NEJMoa2310063

2. Ibrutinib retreatment in Phase 2 CAPTIVATE study:

https://ash.confex.com/ash/2023/webprogram/Paper187128.html

Hodgkin Lymphoma

1. S1826 outcomes in older adults:

https://ash.confex.com/ash/2023/webprogram/Paper180114.html

Diffuse Large B-cell Lymphoma

1. Smart STOP study: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma

https://ash.confex.com/ash/2023/webprogram/Paper180381.html

2. Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

https://ash.confex.com/ash/2023/webprogram/Paper177588.html